Zetia, Ezetimibe News

For the past several years, drug industry experts have spoken in terms of the "patent cliff," the period when the patents covering several blockbuster drugs are set to expire, thus leaving their manufacturers with a big, gaping hole in their revenues as those drugs face competition from generics.

A considerable number of patients with severely elevated LDL-C do not achieve recommended treatment targets, despite treatment with statins.

A molecule in liver cell membranes that plays a role in cholesterol uptake also enables hepatitis C virus to enter cells, according to research reported in the January 8, 2012, advance online edition of Nature Medicine.

San Rafael doctors have taken at least $60,000 from drug companies over the last three years for meals, trips and lectures.

Main Category: Liver Disease / Hepatitis Also Included In: Cholesterol ; Transplants / Organ Donations Article Date: 26 Jan 2012 - 0:00 PST A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the ... (more)

The FDA rejected a new indicationA for Merck's Vytorin and Zetia in chronic kidney disease patients.

U.S. health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving its use for that purpose.

A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

Objective: To compare cardiovascular outcomes between patients initiating adjunct therapy with either niacin extended-release for broader lipid panel management or ezetimibe for continued LDL-C reduction.

Background: Ezetimibe's excellent tolerability and approximately 20% LDL lowering effect have made it the most commonly prescribed 2nd line lipid lowering agent after statins.

From the Department of Medicine B, The Heart Center, Rigshospitalet, Copenhagen, Denmark ; Department of Medicine, Institution of Public Health and Clinical Medicine, UmeA University, SkelleftA , Sweden ; Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany ; Institute of Clinical Medicine, Department of Internal Medicine and Biocenter Oulu, ... (more)